Literature DB >> 11312251

Physical interaction of human papillomavirus virus-like particles with immune cells.

D M Da Silva1, M P Velders, J D Nieland, J T Schiller, B J Nickoloff, W M Kast.   

Abstract

Human papillomavirus virus-like particles (HPV VLP) and chimeric VLP are immunogens that are able to elicit potent anti-viral/tumor B and T cell responses. To investigate the immunogenicity of VLP, we determined which cells of the immune system are able to bind HPV-16 VLP. VLP were found to bind very well to human and mouse immune cells that expressed markers of antigen-presenting cells (APC) such as MHC class II, CD80 and CD86, including dendritic cells, macrophages and B cells. mAb blocking studies identified Fc gamma RIII (CD16) as one of the molecules to which the VLP can bind both on immune cells and foreskin epithelium. However, transfection of a CD16(-) cell line with CD16 did not confer binding of VLP. Splenocytes from Fc gamma RIII knockout mice showed a 33% decrease in VLP binding overall and specifically to subsets of APC. These combined data support a role for CD16 as an accessory molecule in an HPV VLP-receptor complex, possibly contributing to the immunogenicity of HPV VLP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11312251     DOI: 10.1093/intimm/13.5.633

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  17 in total

Review 1.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

2.  Human papillomavirus capsids preferentially bind and infect tumor cells.

Authors:  Rhonda C Kines; Rebecca J Cerio; Jeffrey N Roberts; Cynthia D Thompson; Elisabet de Los Pinos; Douglas R Lowy; John T Schiller
Journal:  Int J Cancer       Date:  2015-10-27       Impact factor: 7.396

3.  Study of infectious virus production from HPV18/16 capsid chimeras.

Authors:  Horng-Shen Chen; Jennifer Bromberg-White; Michael J Conway; Samina Alam; Craig Meyers
Journal:  Virology       Date:  2010-07-03       Impact factor: 3.616

4.  Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses.

Authors:  Ling Ye; Zhiyuan Wen; Ke Dong; Lei Pan; Zhigao Bu; Richard W Compans; Huizhong Zhang; Chinglai Yang
Journal:  J Biomed Biotechnol       Date:  2010-05-25

5.  Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.

Authors:  K Jyotsna Reddy; Babak Banapour; David E Anderson; Sang H Lee; Juan P Marquez; Maria P Carlos; Jose V Torres
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

6.  Ebola virus-like particles protect from lethal Ebola virus infection.

Authors:  Kelly L Warfield; Catharine M Bosio; Brent C Welcher; Emily M Deal; Mansour Mohamadzadeh; Alan Schmaljohn; M Javad Aman; Sina Bavari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

7.  Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.

Authors:  Alfonso García-Piñeres; Allan Hildesheim; Lori Dodd; Troy J Kemp; Marcus Williams; Clayton Harro; Douglas R Lowy; John T Schiller; Ligia A Pinto
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

Review 8.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

9.  Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry.

Authors:  Miriam Triyatni; Bertrand Saunier; Padma Maruvada; Anthony R Davis; Luca Ulianich; Theo Heller; Arvind Patel; Leonard D Kohn; T Jake Liang
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 10.  Mechanisms of cell entry by human papillomaviruses: an overview.

Authors:  Caroline A J Horvath; Gaëlle A V Boulet; Virginie M Renoux; Philippe O Delvenne; John-Paul J Bogers
Journal:  Virol J       Date:  2010-01-20       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.